Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

US8710058B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Axel Becker · Altrip, DE
• Clemens Kuehn · Darmstadt, DE
• Christoph Saal · Otzberg, DE
• Oliver Schadt · Rodenbach, DE
• Dieter Dorsch · Ober-Ramstadt, DE
• Heinz-Hermann Bokel · Darmstadt, DE
• Frank Stieber · Heidelberg, DE
• Cristina Donini · Mandello del Lario, IT

Key dates

• Filing date: Dec 4, 2009
• Grant date: Apr 29, 2014
• Expiry date: Dec 4, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the present invention concern 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The compound, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, has the following structural formula:The hydrochloride solvates and crystalline modifications thereof according to the invention are useful for treatment of physiological and/or pathophysiological conditions, such as cancer, that are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, especially Met-kinase. The present invention further relates to processes of manufacturing these crystalline modifications.